

# Bronchitis - Pipeline Review, H1 2018

<https://marketpublishers.com/r/BFE2B278FE1EN.html>

Date: March 2018

Pages: 68

Price: US\$ 2,000.00 (Single User License)

ID: BFE2B278FE1EN

## Abstracts

Bronchitis - Pipeline Review, H1 2018

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H1 2018, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 3, 3 and 1 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Bronchitis - Overview
- Bronchitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bronchitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchitis - Companies Involved in Therapeutics Development
- Advanced Inhalation Therapies (AIT) Ltd
- AstraZeneca Plc
- DBV Technologies SA
- F. Hoffmann-La Roche Ltd
- Han Wha Pharma Co Ltd
- Icure Pharmaceutical Inc
- Kyorin Pharmaceutical Co Ltd
- Merck & Co Inc
- Mucosis BV (Inactive)
- Orbis Biosciences Inc
- Therabron Therapeutics Inc
- Bronchitis - Drug Profiles
- alteplase - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alvelestat - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CG-367 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

formoterol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lasufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirfenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YJP-40 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Bronchitis - Dormant Projects

Bronchitis - Discontinued Products

Bronchitis - Product Development Milestones

Featured News & Press Releases

Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings

Feb 03, 2014: AIT to Present Noxcurebr at the Annual Meeting Of The Israeli Association Of Clinical Pediatrics

Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants

Jan 15, 2013: DBV Technologies and INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Bronchitis, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products by Stage and Target, H1 2018  
Number of Products by Stage and Mechanism of Action, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Bronchitis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018  
Bronchitis - Pipeline by AstraZeneca Plc, H1 2018  
Bronchitis - Pipeline by DBV Technologies SA, H1 2018  
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018  
Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H1 2018  
Bronchitis - Pipeline by Icure Pharmaceutical Inc, H1 2018  
Bronchitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018  
Bronchitis - Pipeline by Merck & Co Inc, H1 2018  
Bronchitis - Pipeline by Mucosis BV (Inactive), H1 2018  
Bronchitis - Pipeline by Orbis Biosciences Inc, H1 2018  
Bronchitis - Pipeline by Therabron Therapeutics Inc, H1 2018  
Bronchitis - Dormant Projects, H1 2018  
Bronchitis - Dormant Projects, H1 2018 (Contd..1), H1 2018  
Bronchitis - Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Bronchitis, H1 2018  
Number of Products under Development by Companies, H1 2018  
Number of Products by Top 10 Targets, H1 2018  
Number of Products by Stage and Top 10 Targets, H1 2018  
Number of Products by Top 10 Mechanism of Actions, H1 2018  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018  
Number of Products by Routes of Administration, H1 2018  
Number of Products by Stage and Routes of Administration, H1 2018  
Number of Products by Molecule Types, H1 2018  
Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Advanced Inhalation Therapies (AIT) Ltd  
AstraZeneca Plc  
DBV Technologies SA  
F. Hoffmann-La Roche Ltd  
Han Wha Pharma Co Ltd  
Icure Pharmaceutical Inc  
Kyorin Pharmaceutical Co Ltd  
Merck & Co Inc  
Mucosis BV (Inactive)  
Orbis Biosciences Inc  
Therabron Therapeutics Inc



## I would like to order

Product name: Bronchitis - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/BFE2B278FE1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BFE2B278FE1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970